Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M312875200 on January 13, 2004

J. Biol. Chem., Vol. 279, Issue 15, 15130-15141, April 9, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/15/15130    most recent
M312875200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hadri, K. E.
Right arrow Articles by Fève, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hadri, K. E.
Right arrow Articles by Fève, B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

In Vitro Suppression of the Lipogenic Pathway by the Nonnucleoside Reverse Transcriptase Inhibitor Efavirenz in 3T3 and Human Preadipocytes or Adipocytes*

Khadija El Hadri{ddagger}§, Martine Glorian{ddagger}§, Christelle Monsempes{ddagger}, Marie-Noëlle Dieudonné¶, René Pecquery¶, Yves Giudicelli¶, Marise Andreani{ddagger}, Isabelle Dugail||, and Bruno Fève{ddagger}**

From the {ddagger}UMR CNRS 7079-Université Paris VI and ||INSERM U465, Centre de Recherches Biomédicales des Cordeliers, 15 rue de l'Ecole de Médecine, 75006 Paris, France, and Service de Biochimie, Faculté de Médecine de Paris-Ile de France-Ouest, Université Versailles Saint-Quentin, Centre Hospitalier de Poissy, 78303 Poissy Cedex, France

Received for publication, November 25, 2003 , and in revised form, December 22, 2003.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
A serious metabolic syndrome combining insulin-resistance, dyslipidemia, central adiposity, and peripheral lipoatrophy has arisen in HIV-infected patients receiving highly active antiretroviral therapy. The aim of this work was to examine the effects of the nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz on adipocyte differentiation and metabolism. When induced to differentiate in the presence of efavirenz (5–50 µM), 3T3-F442A preadipocytes failed to accumulate cytoplasmic triacylglycerol droplets. This phenomenon was rapidly reversible and was also readily detectable in the 3T3-L1 preadipose cell line and in primary cultures of human preadipocytes. When applied to mature 3T3-F442A adipocytes, efavirenz induced a delayed and moderate reduction in cell triglyceride content. Measurement of [3H]deoxyglucose uptake, basal and agonist-stimulated lipolysis, and cell viability indicated that these pathways are not involved in efavirenz effects on triacylglycerol accumulation. By contrast, we found that the NNRTI induced a dramatic dose- and time-dependent decrease in gene and protein expression of the lipogenic transcription factor sterol regulatory element-binding protein-1c (SREBP-1c). Adipose conversion was only altered at the highest efavirenz concentrations, as suggested by the mild reduction in peroxisome proliferator-activated receptor-{gamma} and CCAAT/enhancer-binding protein-{alpha}. CCAAT/enhancer-binding protein-{beta} remained unchanged. The inhibition of SREBP-1c expression was accompanied by a sharp reduction in the expression of SREBP-1c target genes and in the adipocyte lipogenic activity in efavirenz-treated cells. Finally, the inhibitory effect of efavirenz on cell triglyceride accumulation was prevented by directly providing free fatty acids to the cells and was reversed by overexpression of a dominant positive form of SREBP-1c, reinforcing the implication of this transcription factor in the antilipogenic effect of the drug. When considered together, these results demonstrate for the first time that the NNRTI efavirenz induces a strong inhibition of the SREBP-1c-dependent lipogenic pathway that might contribute to adipose tissue atrophy.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The widespread use of highly active antiretroviral therapy (HAART)1 has radically transformed the prognosis of HIV-infected patients in the developed countries (1, 2). Intensive therapy of HIV infection with HAART, which combines various protease inhibitors (PIs), nucleoside analogue reverse transcriptase inhibitors (NRTIs), and nonnucleoside reverse transcriptase inhibitors (NNRTI), dramatically reduces viral load and increases CD4 T cell count (1). Whereas a successful control of HIV infection is now possible, withdrawal of HAART leads to a prompt recovery of viremia (3), thus implying a prolonged and potentially life-long treatment to prevent viral replication. Currently, the recommended therapy for HIV-infected patients includes one or two PIs combined with two NRTI or two NRTI combined with one NNRTI. Blockade of the HIV protease inhibits cleavage and maturation of the viral polyprotein precursor, leading to production of noninfectious viral particles (4). The HIV reverse transcriptase is required to copy the viral RNA genome and is targeted either by chain-terminating analogues (NRTI) or by noncompetitive inhibitors (NNRTI) (5).

Unfortunately, long term HAART has been associated with a unique and unexpected lipodystrophic syndrome involving altered body fat distribution and disturbances of glucose and lipid metabolism (6–8). Most patients receiving this treatment develop metabolic abnormalities, which include dyslipidemia (elevated plasma triglycerides and cholesterol), increased visceral and dorsocervical adipose tissue, and peripheral lipoatrophy. These patients were also found to have elevated fasting insulin or C-peptide levels (9, 10), suggesting that these individuals develop insulin resistance. It is now recognized that patients receiving an antiretroviral therapy have an increased risk of cardiovascular disease (9, 11, 12), emphasizing the medical significance of the HAART-associated lipodystrophy and metabolic abnormalities.

Which component of the antiretroviral regimen or whether the HIV infection itself is responsible for the HAART-associated metabolic syndrome is still a matter of controversy. Emergence of the syndrome has been correlated temporally with the widespread use of PIs, but similar symptoms have been observed in therapy naive HIV-infected patients (13) and in patients receiving treatments excluding PIs (14–16). The mechanisms underlying the onset of the syndrome may represent a complex response to independent factors, such as a specific drug or a combination of drugs, long lasting viral infection, or effective viral suppression.

Studies on healthy subjects or on HIV-infected patients who have never received PIs have shown that dyslipidemia and insulin resistance can occur several months before the emergence of lipodystrophy (7, 9). Conversely, glycemic and lipidic disturbances are also observed in genetic syndromes of generalized or partial lipodystrophy (17) and in transgenic models of lipoatrophy resulting from manipulation of major adipogenic transcription factors (18–20), suggesting that an initial lack of adipogenesis or a loss in adipose tissue may be involved in insulin resistance and metabolic complications.

A considerable sum of works has highlighted the molecular mechanisms of adipogenesis (21). Adipocyte differentiation involves a sequential and coordinated action of several transcription factors that, in turn, regulate the expression of adipocyte-specific genes and proteins. At least two classes of transcription factors serve key roles in the regulation of adipogenesis, CCAAT/enhancer-binding proteins (C/EBPs), and peroxisome proliferator-activated receptor-{gamma} (PPAR{gamma}). Following the initial and transient increase in C/EBP{beta} and -{delta}, PPAR{gamma} and C/EBP{alpha} promote the expression of a number of adipose-specific markers, allowing acquisition of an enlarged rounded shape and the progressive accumulation of cytoplasmic triacylglycerol droplets. In addition, adipocyte differentiation is enhanced by the basic helix-loop-helix-leucine zipper transcription factor sterol regulatory element-binding protein-1c/adipocyte determination and differentiation factor-1 (SREBP-1c/ADD1). SREBP-1c promotes lipogenic enzyme gene expression (22–24), transactivates the PPAR{gamma} promoter (25), and stimulates production of an unknown PPAR{gamma} ligand (26). Thus, PPAR{gamma}, C/EBP{alpha}, and SREBP-1c act in concert to induce and maintain the adipocyte phenotype.

Since the adverse effects of a single compound on a given tissue or cell type are difficult to determine in patients receiving a combination of several classes of antiretroviral drugs, in vitro models have been used to examine the exact influence of these treatments on adipocyte development or metabolism. In this regard, contradictory results have been published, few studies showing a positive effect (27) and more numerous ones showing a negative effect (28–33) of PIs on adipocyte differentiation. The inhibitory effects of PIs on adipogenesis have been related to a decreased expression in C/EBP{alpha} (31) or PPAR{gamma} (31, 32) or to an altered expression or intranuclear localization of SREBP-1c (32, 34, 35). Interestingly, abnormal changes in SREBP-1c were also found in white adipose tissue of ritonavir-treated mice (36) and in lipoatrophic tissue from HIV-infected patients under HAART (37). Several authors have hypothesized that PI-induced alterations in SREBP-1c may be a major phenomenon in the setting of the metabolic syndrome (37, 38). In fat cells, in addition to their effects on adipogenesis per se, PIs also impair insulin signaling events and glucose transport (39, 40), increase lipolysis (30, 40), and stimulate apoptosis (31, 41).

With regard to the major side effects associated with the use of PIs, alternative therapies have been proposed to replace the PIs with abacavir (42, 43) or by the NNRTI nevirapine (44–46) or efavirenz (47, 48). These approaches appear successful to control HIV infection, particularly with the NNRTI (43). The most common side effects encountered with NNRTI are cutaneous rash and central nervous system disturbances such as dizziness, whereas these compounds are generally well tolerated at the metabolic level. However, recent works have reported that treatment with the NNRTI efavirenz can be associated with dyslipidemia (49–51) and that this compound can accumulate in adipose tissue (52). These observations prompted us to examine whether efavirenz alters adipocyte development and metabolism. Surprisingly, we demonstrate that efavirenz primarily reduces cell triglyceride accumulation in several in vitro systems of adipogenesis, including a human model. This effect of efavirenz on triglyceride stores seems essentially related to a decrease in SREBP-1c expression, with a consecutive alteration in the lipogenic pathway.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Subjects—Adipose tissue samples were obtained from deep (mesenteric) or abdominal subcutaneous deposits from men (age 56 ± 6 years) or women (age 69 ± 3 years) undergoing surgical intervention. Body mass index ranged from 22.9 to 32.4 kg/m2, and subjects had no metabolic or endocrine diseases. This study was approved by local ethics committee.

Cell Culture and Treatment—Murine 3T3-F442A preadipocytes were grown until confluence at 37 °C in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) with 4.5 g/liter D-glucose, 10% fetal calf serum (Invitrogen), and penicillin/streptomycin (100 units/ml penicillin, 50 µg/ml streptomycin). After confluence, 3T3-F442A adipose conversion was obtained in the presence of the same culture medium supplemented with 170 nM insulin. 3T3-L1 adipocyte differentiation was initiated by the addition of 100 µM methyl-isobutylxanthine, 170 nM insulin, and 250 nM dexamethasone for 48 h, and then cells were refed by DMEM containing 10% fetal calf serum and 170 nM insulin.

Human preadipocytes were obtained from adipose tissue samples by collagenase digestion as previously described (53). The floating adipocytes were discarded, and the infranatant containing the stromal vascular fraction was successively filtered through 150- and 25-µm nylon screens. The filtrate was centrifuged at 600 x g for 10 min. After two washes, cells were plated into cell culture dishes at a density of 2–4 x 104 cells/cm2 with DMEM/Ham's F-12 (1:1, v/v) supplemented with 10% fetal calf serum and antibiotics and cultured at 37 °C under an atmosphere of air/CO2 (95:5, v/v). After plating, cells were extensively washed and maintained under the same conditions until confluence (3–4 days following plating). To induce human preadipocyte differentiation, cells were then shifted in a chemically defined medium consisting of DMEM/Ham's F-12 supplemented with 80 nM insulin, 10 µg/ml transferrin, 0.2 nM L-T3, 100 nM hydrocortisone, and antibiotics and for the first 3 days with 200 µM methyl-isobutylxanthine and 1 µg/ml troglitazone.

When mentioned, cells were cultured in the absence (Me2SO alone) or in the presence of efavirenz (dissolved in Me2SO) at concentrations and periods of time indicated under "Results." The final concentration of Me2SO never exceeded 0.025%. During the period of efavirenz exposure, the medium was changed daily for control and drug-treated cells. The powdered form of efavirenz was a generous gift of Bristol-Myers Squibb Laboratories.

Cell Extracts, Biochemical Determinations, and Enzyme Assays— Cultured preadipose or adipose cells were washed twice with phosphate-buffered saline (PBS), harvested, and homogenized in Tris (25 mM), pH 7.5, EDTA (1 mM). A fraction of the homogenate was stored at -80 °C. The remaining fraction was centrifuged at 10,000 x g for 10 min at 4 °C, and the supernatant was kept at -80 °C until use. Aliquots of homogenates and supernatants were used to determine protein content by the method of Lowry (54), using bovine serum albumin (BSA) as a standard. Triglyceride content was determined on homogenates with PAP150 triglyceride kit (Biomérieux, Marcy L'Etoile, France).

Glycerol-3-phosphate dehydrogenase (G3PDH) activity was assayed by recording the initial rate of oxidation of NADH at 340 nm at 25 °C (55).

Cell viability was assessed by testing lactate dehydrogenase activity in the culture medium. Media were assayed by measuring the rate of decrease in A340 in the presence of pyruvate, as described earlier (56).

Lipolysis Experiments—Lipolysis was assessed as glycerol release from adherent 3T3-F442A adipocytes in 24-well plates. Adipocyte monolayers were washed with Krebs-Ringer buffer containing 12 mM Hepes (KRH) (pH 7.4), supplemented with 1% fatty acid-free BSA, 4.5 g/liter D-glucose, and 1 mM ascorbate and 50 µg/ml Na2S2O5 as antioxidants. Cells were incubated for 2 h at 37 °C in the absence or in the presence of 10 µM (-)-isoproterenol or 10 µM forskolin. Aliquots of the incubation medium were removed and frozen at -20 °C until glycerol determination. Glycerol was measured by an enzymatic method using a commercial kit provided by Roche-Biopharm.

[3H]Glucose Incorporation in Total Lipids—Measurement of [3H]glucose incorporation in total lipids was used as an index of lipogenic activity. 3T3-F442A cell cultures in 12-well plates were rinsed three times with KRH buffer and then incubated for 1 h at 37 °C in KRH containing 5 mM [1-3H]D-glucose ([3H]glucose) (1 µCi/well; 1 mCi/mmol; ICN Biochemicals, Orsay, France). Cells were washed with ice-cold PBS, harvested, and pelleted by centrifugation. After discarding the supernatant, cell total lipids were extracted by the chloroform/methanol procedure of Folch et al. (57). The lipid-containing lower chloroform phase was finally evaporated and radioactivity was measured by scintillation counting.

Determination of 2-Deoxyglucose Uptake—Uptake of glucose was determined using [1,2-3H]deoxyglucose ([3H]DOG) (ICN Biomedicals, Orsay, France), a nonmetabolizable analogue of glucose. 3T3-F442A adipocytes cultured in 12-well plates were rinsed three times with KRH and then preincubated for 2 h at 37 °C in 1 ml of the KRH buffer containing 0.1% BSA. When mentioned, insulin was added during this preincubation period 1 h before measurement of hexose transport. Glucose uptake was initiated by the addition of [3H]DOG (0.1 mM; 1 µCi/well). After 5 min at 37 °C, the assay was stopped by aspiration, and cells were rinsed three times with ice-cold PBS. Cells were solubilized with 1% SDS, and radioactivity was determined by scintillation counting. Non-carrier-mediated glucose uptake, estimated by the addition of 10 µM cytochalasin B in parallel wells, accounted for less than 3% of total glucose transport.

RNA Analysis—Total RNA was extracted from 3T3-F442A and 3T3-L1 cells by the method of Cathala (58) and from human cells by the procedure of Chomczynski and Sacchi (59).

For real time RT-PCR analysis, total RNA was first digested for 15 min at 37 °C with 0.1 units of RNase-free DNase I (RQ1 DNase, Promega)/µg of nucleic acid in 40 mM Tris-HCl, pH 7.9, 10 mM NaCl, 6 mM MgCl2, and 10 mM CaCl2. After phenol/chloroform extraction and ethanol precipitation, RNA (0.25–1 µg/sample) was reverse transcribed with Moloney murine leukemia virus-RT (200 units/µg) (Invitrogen) in the presence of 10 µM random hexanucleotides (Amersham Biosciences) and 400 µM of each dNTP in a final volume of 40 µl consisting of 50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 mM MgCl2, and 10 mM dithiothreitol. After a 1-h incubation at 42 °C, Moloney murine leukemia virus-RT was heat-inactivated. To ensure that subsequent amplification did not derive from contaminant genomic DNA, a control without Moloney murine leukemia virus-RT was included in parallel for each RNA sample.

Reverse transcribed mRNAs were amplified on ICycler thermal cycler (Bio-Rad), using the SYBR green fluorescence method, and were analyzed with the ICycler IQTM real time detection system software. The PCR assay was performed under a final volume of 25 µl, starting from 5–100 ng of reverse transcribed total RNA, in the presence of a 250 nM concentration of each sense and antisense oligonucleotide, 125 µM each dNTP, 2.5 mM MgCl2, 7 nM fluorescein, 0.5 unit of Taq DNA polymerase in its recommended buffer, including 1x SYBR green (Eurogentec). To verify that fluorescence generated by SYBR green incorporation into double-stranded DNA was not overestimated by contaminations resulting from residual genomic DNA amplification and/or from primer dimer formation, controls without reverse transcriptase and without DNA template or reverse transcriptase were included in each experiment. Moreover, RT-PCR products were analyzed in a postamplification fusion curve to ensure that a single amplicon was obtained. Ribosomal 18 S RNA and glyceraldehyde-3-phosphate dehydrogenase mRNA levels were used to normalize the initial amounts of cDNA in 3T3 and human cells, respectively. To measure PCR efficiency, serial dilutions of reverse transcribed RNA were amplified in the presence of the different sets of primers, then cycle threshold (CT) was plotted against the initial amounts of reverse transcribed RNA, and the slope of the resulting curve allowed calculation of PCR efficiency. For all experiments, PCR efficiencies were close to 1 (PCR efficiency = 1.03 ± 0.03, n = 84), indicating a doubling of DNA at each PCR cycle, as theoretically expected. Thus, taking into account standardization with 18 S or glyceraldehyde-3-phosphate dehydrogenase amplification products, it was possible to compare the relative levels of the tested transcripts between the different experimental conditions. Quantification of mRNA was carried out by comparison of the number of cycles required to reach reference and target threshold values ({delta}-{delta} CT method; see, on the World Wide Web, www.bio.com/newsfeature). Sequences of the sense and antisense oligonucleotides corresponding to the different tested genes are given in Table I.


View this table:
[in this window]
[in a new window]
  		TABLE I
Primer sequences of genes tested in real time RT-PCR The abbreviations of the genes, their full names, and 5' to 3' nucleotide sequences of the sense and antisense primers are presented.

 
Western Blot Analysis—Nuclear extracts were prepared from 3T3-F442A adipocytes as previously described (60). Proteins (30 µg/lane) were separated on an SDS-7.5% polyacrylamide gel and electroblotted onto a 0.45-µm polyvinylidene difluoride membrane (Immobilon-P; Millipore Corp.) in 0.1% SDS, 192 mM glycine, and 25 mM Tris, pH 8.3. The membrane was dept in methanol, then blocked with 5% BSA, 0.1% Tween 20 in PBS for 1 h at room temperature. After washing in PBS containing 0.1% Tween 20, the membrane was incubated overnight at 4 °C with primary antibodies (rabbit polyclonal antibodies against SREBP-1c or C/EBP{alpha}(1:1000 dilution); murine monoclonal antibody against PPAR{gamma}(1:250 dilution) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) in 0.1% Tween 20-PBS, 2% BSA. After three washes with 0.1% Tween 20-PBS, the membrane was incubated for 1 h at room temperature with horseradish peroxidase-conjugated anti-rabbit (1:20,000 dilution) or anti-mouse (1:2000 dilution) IgG (Sigma). The membrane was then washed in 0.1% Tween 20-PBS. Detection of immune complex was performed using an enhanced chemiluminescence detection kit for Western blot (Amersham Biosciences).

Adenofection Experiments—The adenovirus vector containing the transcriptionally active dominant positive (DP) N-terminal part (amino acids 1–403) of rat SREBP-1c, called Ad.SREBP-1c DP, was generated as already described (61). Ad.SREBP-1c DP was under control of a cytomegalovirus promoter, and a green fluorescent protein was coexpressed to monitor transfection efficiency. The adenovirus vector containing the major late promoter with no exogenous gene, called Ad.null, was used as a control. After propagation in the HEK293 cell line, adenoviral vectors were purified by cesium chloride density centrifugation and stored at -80 °C until use. Adenofection was performed at a multiplicity of infection of 500 (500 plaque-forming units/cell) that is known to achieve an optimal infection efficiency in 3T3 adipocytes (62). Viral infection was controlled by green fluorescent protein expression and was similar between Ad.null- and Ad.SREBP-1c DP-infected cells. Expression of SREBP-1c target genes and cell triglyceride content were examined 48 and 96 h following infection, respectively.

Statistical Analysis—Results are presented as mean ± S.E. The statistical comparison of data between groups was assessed with analysis of variance (STATVIEWTM software). A p value of <0.05 was considered as the threshold of statistical significance.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Efavirenz Preferentially Inhibits Triglyceride Accumulation during Adipocyte Differentiation—To evaluate the effects of efavirenz on preadipocyte differentiation, 3T3-F442A were grown until confluence and then cultured for various periods of time in the absence or in the presence of the drug, with a concentration range that is comparable with that observed in the plasma of treated patients (63, 64).

In a first set of experiments, 3T3-F442A cells were exposed from confluence to various efavirenz concentrations for 7 days, and cell triglyceride content was tested. Triglyceride content decreased significantly from 10 µM efavirenz and then continued to markedly decline with increasing doses (Fig. 1A). The effect was maximal at 50 µM, with a 94% reduction in triglyceride content as compared with control cells. The half-maximal effect was obtained at about 20 µM efavirenz.



View larger version (34K):
[in this window]
[in a new window]
  		FIG. 1.
Effect of efavirenz on triglyceride accumulation during 3T3-F442A and 3T3-L1 adipose conversion. A, from confluence (day 0), 3T3-F442A cells were cultured for 7 days in the absence or in the presence of various concentrations of efavirenz, and cell triglyceride content was tested. Results represent the mean ± S.E. of 4–10 separate experiments. B, from confluence, 3T3-F442A were maintained in the absence (triangles) or in the presence (squares)of40 µM efavirenz for the indicated time. Results represent the mean ± S.E. of 10 independent experiments. C, from confluence (day 0), 3T3-L1 cells were cultured until day 7 in the absence or in the presence of various concentrations of efavirenz and tested for triglyceride content determination. Results represent the mean ± S.E. of 6–10 separate determinations. D, from day 0 (confluence) to day 7, 3T3-F442A or 3T3-L1 cells were cultured in the absence or in the presence of efavirenz (40 µM) and then stained with Oil Red O. *, p < 0.01; **, p < 0.001, efavirenz-treated versus control cells.

 
To examine the time dependence of efavirenz effect on triglyceride content, 3T3-F442A cells were maintained from confluence in the absence or in the presence of 40 µM efavirenz, and cell extracts were prepared at intervals. After 2 days of treatment following confluence, cell triglyceride content was weakly reduced by efavirenz. However, this effect was much more dramatic after 4 days, reaching a maximal 80% decrease in day 7 postconfluent adipocytes (Fig. 1B).

These results drawn from biochemical analysis were also strengthened by cytochemical examination. Acquisition of an enlarged round shape, which usually precedes triacylglycerol accumulation, was slightly delayed in efavirenz-treated as compared with control cells (not shown). However, after a few days following confluence, efavirenz-exposed cells recovered a morphotype similar to that of untreated cells. Obviously, efavirenz potently decreased intracytosolic accumulation of lipid droplets. At day 7 following confluence, efavirenz-treated 3T3-F442A cells displayed a dramatic reduction in the number and size of fat vacuoles as compared with control cells. These striking changes in lipid accumulation were also illustrated by Oil Red O staining (Fig. 1D).

To verify that efavirenz effect on fat stores was not restricted to 3T3-F442A cells, similar studies were also performed on two other models of adipogenesis (i.e. the murine 3T3-L1 preadipose cell line and primary cultures of stromal vascular fraction derived from human adipose tissue). 3T3-L1 preadipocytes were grown to confluence and then induced to differentiate in the absence or in the presence of various efavirenz concentrations. As shown in Fig. 1C, triglyceride content was already decreased by 17% at 10 µM efavirenz and by 50% at 20 µM, with a maximal 88% reduction at 40 µM. The dramatic effect of efavirenz on 3T3-L1 triglyceride stores is also documented by Oil Red O staining (Fig. 1D). The influence of efavirenz on adipogenesis and lipid droplet accumulation was also examined during adipose conversion of human preadipocytes in primary cultures. Cells were grown to confluence in a serum-containing medium and then shifted in a chemically defined medium. Since in vivo, the main part of efavirenz is combined to serum proteins (65), this implied the use of much lower drug concentrations. From confluence, human preadipocytes were cultured for 7 days in the absence or in the presence of 2 or 4 µM efavirenz. Fig. 2, A and B, illustrates that a chronic exposure to 4 µM efavirenz caused a dramatic decrease in fat droplet accumulation. This was confirmed by the dose-dependent inhibiting effect of the NNRTI on cell triglyceride content (Fig. 2C). With the proviso of the limited number of human adipose tissue samples (n = 6), no obvious gender- or depot-specific difference was detectable.



View larger version (82K):
[in this window]
[in a new window]
  		FIG. 2.
Dose-dependent effect of efavirenz on triglyceride accumulation during human preadipocyte differentiation. A and B, microscopic view (x 400) of human preadipocytes cultured for 7 days from confluence in a chemically defined medium in the absence A or in the presence B of efavirenz (4 µM). C, triglyceride content of human preadipocytes cultured for 7 days in the absence or in the presence of 2 or 4 µM efavirenz. Results are expressed as the percentage of control triglyceride content and represent the mean ± S.E. of four independent determinations. *, p < 0.01; efavirenz-treated versus control cells.

 
Taken together, our results drawn from three distinct models of adipocyte differentiation suggest that efavirenz exposure during adipose conversion potently prevents triacylglycerol accumulation.

To examine whether this effect was reversible, 3T3-F442A cells were initially cultured from day 0 to day 7 in the presence of 40 µM efavirenz and then allowed to recover for an additional 8 days. As shown above, chronic efavirenz exposure during preadipocyte differentiation prevented triglyceride accumulation (Fig. 3). When efavirenz treatment was pursued, cell triglyceride content remained low and maximally represented 15% of the control value at day 15 following confluence. On the contrary, efavirenz withdrawal allowed 3T3-F442A cells to progressively recover a triglyceride content that was not significantly different from that of control cells in day 15 postconfluent 3T3-F442A adipocytes. Thus, the efavirenz-induced down-regulation in triglyceride accumulation was spontaneously and rapidly reversible.



View larger version (12K):
[in this window]
[in a new window]
  		FIG. 3.
Spontaneous reversibility of efavirenz effect on 3T3-F442A cell triglyceride content after drug withdrawal. 3T3-F442A cells were initially cultured from confluence (day 0) in the absence or in the presence of efavirenz (40 µM) for 7 days. Thereafter, control cells were maintained without drug addition, whereas cells previously exposed to the NNRTI were divided in two groups; efavirenz (40 µM) was pursued (dark columns), or efavirenz was omitted (open columns). Cell extracts were prepared at the indicated intervals and tested for triglyceride content. Results are expressed as the percentage of control triglyceride value and represent the mean ± S.E. of four independent experiments. *, p < 0.01; **, p < 0.001; n.s., nonsignificant, efavirenz-treated versus control cells, whatever the temporal sequence of efavirenz exposure. #, p < 0.001, cells continuously exposed to efavirenz (day 0 (D0) to day 9, day 0 to day 12, or day 0 to day 15) versus cells with only an initial treatment with efavirenz (day 0 to day 7).

 
Efavirenz Progressively Reduces Triacylglycerol Accumulation in Mature 3T3-F442A Adipocytes—To investigate whether in addition to its effect during adipose conversion, efavirenz could also decrease lipid accumulation in mature adipocytes, we examined the influence of a chronic exposure to the NNRTI on triglyceride content of fully differentiated 3T3–442A adipocytes. In this experiment, the drug was added at day 8 following confluence. As mentioned in Table II, efavirenz at 20 µM did not modify cell triglyceride accumulation. However, we observed an approximately 20% reduction in triglyceride content after a 4- or 8-day exposure to a 40 µM concentration of the drug and even a 40% decrease after a 16-day treatment. Thus, in mature 3T3-F442A adipocytes, a long term treatment with a high dose of efavirenz can decrease triglyceride accumulation.


View this table:
[in this window]
[in a new window]
  		TABLE II
Efavirenz effect on triglyceride accumulation in mature 3T3-F442A adipocytes 3T3-F442A cells were differentiated with fetal calf serum and insulin. Once differentiation was achieved, day 8 postconfluent adipocytes were cultured in the absence or in the presence of efavirenz (20 or 40 µM) for 4, 8, and 16 days. At these intervals, cells extracts were prepared to determine triglyceride content. The percentage of the control value is given in parentheses after the values of triglyceride content. Results represent the mean ± S.E. of 4-10 separate experiments.

 
Efavirenz Primarily Alters the Lipogenic Pathway of Differentiating or Mature 3T3-F442A Adipocytes—In an attempt to identify the cellular and molecular mechanisms by which efavirenz altered cell triglyceride accumulation, several experimental approaches were carried out to support the view that specific biological events could contribute, at least in part, to the observed phenomena. Indeed, the efavirenz-induced decrease in cell triglyceride accumulation could result from a general or specific alteration in the adipogenic process, a decreased activity in the lipogenic pathway, a decreased glucose availability for lipogenesis, an increased lipolytic activity, or even a cytotoxic effect.

First, we ensured that efavirenz did not exert a direct cytotoxic effect on 3T3-F442A preadipocytes or adipocytes. For this purpose, lactate dehydrogenase activity was tested on aliquots of the culture medium of control or drug-treated cells, either during the course of the differentiation process or on mature adipocytes. Whatever the phenotype of 3T3-F442A cells, lactate dehydrogenase activity remained low and was not modified in the presence of the antiretroviral compound (not shown).

To determine whether efavirenz could modulate basal or insulin-stimulated glucose transport, mature 3T3-F442A adipocytes were cultured for 4 days in the absence or in the presence of a 20 or 40 µM concentration of the NNRTI, and then [3H]DOG uptake was determined. Neither basal nor maximal insulin-stimulated [3H]DOG transport was altered by a prior exposure to efavirenz (Table III). Furthermore, we observed no effect of efavirenz (40 µM for 4 days) on EC50 values of insulin for stimulating [3H]DOG uptake (EC50 values of insulin were 1.10 ± 0.19 and 1.31 ± 0.40 nM in control and efavirenz-treated cells, respectively; n = 4; p = 0.66). Thus, efavirenz did not alter basal or insulin-stimulated glucose transport, precluding the possibility that this could represent a major mechanism for efavirenz-induced delipidation.


View this table:
[in this window]
[in a new window]
  		TABLE III
Efavirenz does not alter basal or effector-stimulated glucose uptake or lipolysis Day 7 postconfluent 3T3-F442A cells were cultured in the absence or in the presence of efavirenz (20 or 40 µM) for 4 days. [3H]DOG uptake was then measured under basal conditions or in response to an optimal concentration of insulin (100 nM). Results are expressed in nmol of [3H]DOG/5 min/well and represent the mean ± S.E. of 4-8 separate experiments. We have also tested [3H]DOG uptake in response to various concentrations of insulin (see "Results"). Otherwise, independent cultures were performed to measure lipolysis by determination of glycerol release in the culture medium under basal conditions or in response to an optimal concentration of (-)-isoproterenol (10 µM) or forskolin (10 µM). Results are expressed in nmol of glycerol/h/well and represent the mean ± S.E. of six separate experiments.

 
Another mechanism that could account for the inhibitory effect of efavirenz on adipocyte triglyceride accumulation was an increased rate of lipolysis. Hence, mature 3T3-F442A adipocytes were treated for 4 days with 40 µM efavirenz, and lipolysis was measured under basal or stimulated conditions (Table III). A chronic exposure to efavirenz led to a moderate (32%) but significant decrease in basal lipolysis. However, in response to an optimal concentration of the nonselective {beta}-adrenoreceptor agonist (-)-isoproterenol (10 µM) or of the adenylyl cyclase effector forskolin (10 µM), the NNRTI did not significantly change lipolysis. Thus, an increased basal or effector-stimulated lipolytic activity was not involved in the efavirenz-induced down-regulation in cell triglyceride content.

We then tested whether efavirenz impaired lipogenesis (i.e. de novo fatty acid synthesis from glucose). [3H]glucose incorporation into total lipids was used as an index of the lipogenic activity. Table IV shows that following a 4–7-day treatment with efavirenz, there was a clear decrease in [3H]glucose incorporation into lipids. It was noteworthy that the efavirenz effect tended to blur when the drug was applied to terminally differentiated cells. This antilipogenic effect of efavirenz was also dose-dependent, with a half-maximal concentration of about 20 µM (not shown).


View this table:
[in this window]
[in a new window]
  		TABLE IV
Efavirenz reduces [3H]glucose incorporation into lipids in 3T3-F442A cells 3T3-F442A cells were cultured in the absence or in the presence of efavirenz (40 µM) for various periods of time: day 0 (confluence) to day 7 (D0-D7), day 5 to day 9 (D5-D9), day 7 to day 11 (D7-D11), and day 9 to day 13 (D9-D13). At the end of efavirenz exposure, cells were incubated for 1 h in KRH buffer containing 5 mM [3H]glucose. After washing, [3H]glucose incorporation in total lipids was measured. Results are expressed in nmol of glucose incorporated/h/well and represent the mean ± S.E. of 6-12 independent experiments. The percentage of the control value is given in parentheses after the value of [3H]glucose incorporation.

 
Since efavirenz seemed to primarily alter the lipogenic pathway, we wondered whether the limiting effects of the NNRTI on cell triglyceride accumulation could be circumvented by directly providing exogenous fatty acids to the cells. From confluence, 3T3-F442A cells were maintained for 7 days without or with 40 µM efavirenz and in the absence or in the presence of various concentrations of Intralipid as an exogenous source of free fatty acids. As expected, the Intralipid addition provoked a moderate but significant increase in cell triglyceride accumulation, with a maximal effect at 100 µg/ml Intralipid (Fig. 4). Overall, the dramatic efavirenz-induced decrease in cell triglyceride content was prevented by Intralipid in a dose-dependent manner. As shown in Fig. 4, the effect of the NNRTI was completely abolished in the presence of 300 µg/ml Intralipid. This result demonstrates that the down-regulation of adipocyte lipid stores caused by the NNRTI can be prevented by directly providing fatty acids and strongly suggests that the alteration in the lipogenic pathway is the primary site for efavirenz action.



View larger version (13K):
[in this window]
[in a new window]
  		FIG. 4.
Efavirenz effect on triacylglcerol accumulation is prevented in the presence of Intralipid. 3T3-F442A cells were cultured from confluence in the absence (squares) or in the presence (triangles)of efavirenz (40 µM) and in the absence or in the presence of various concentrations of Intralipid. Cell extracts were prepared at day 7 following confluence and tested for triglyceride content (in µM). Results represent the mean ± S.E. of six independent experiments. *, p < 0.05; **, p < 0.001, efavirenz- or Intralipid-treated cells versus control cells. #, p < 0.01; ##, p < 0.001, cells exposed to Intralipid plus efavirenz versus cells treated with efavirenz alone.

 
Molecular Mechanisms of Efavirenz Antilipogenic Effects— Our initial biochemical determinations (see Fig. 1) indicated that from a concentration of 10 µM, efavirenz significantly reduced triglyceride accumulation in differentiating adipocytes. This effect could be related to an alteration in specific events of the differentiation process. It was thus conceivable that efavirenz prevented cell lipid accumulation by a reduction in the expression and/or function of key adipogenic transcription factors. It is now well recognized that the marked and specific phenotypic changes occurring during adipocyte differentiation are related to variations in the expression level of many genes. Genetic reprogramming is under the control of key adipogenic transcription factors such as PPAR{gamma}, C/EBP{alpha} and -{beta}, and SREBP-1c (21).

As a first step to study the influence of efavirenz on the expression of adipogenic transcription factors, 3T3-F442A cells were exposed from confluence to various drug concentrations (5–50 µM) for 7 days, and SREBP-1c, PPAR{gamma}, and C/EBP{alpha} and C/EBP{beta} mRNA steady state levels were analyzed by real-time RT-PCR. G3PDH activity, which reflects the extent of cell differentiation (66), was also examined in parallel. As shown in Fig. 5 (left panels), three different patterns of response to efavirenz were observed. The first pattern was the one detected with SREBP-1c mRNA. Efavirenz provoked a dramatic down-regulation in SREBP-1c mRNA levels, which was detectable at low concentrations (34% inhibition at 5 µM). There was a maximal 98% decrease at 50 µM of the compound and a half-maximal effect between 5 and 10 µM. The second pattern includes those PPAR{gamma} and C/EBP{alpha} mRNAs and G3PDH activity. In this group, gene expression or enzyme activity was only moderately suppressed by exposure to low efavirenz concentrations, with a more pronounced effect at 40 and 50 µM efavirenz (50% decrease for PPAR{gamma}, 70–80% for C/EBP{alpha}, and 90% for G3PDH activity). Finally, some genes such C/EBP{beta} remained roughly unaffected by NNRTI exposure.



View larger version (38K):
[in this window]
[in a new window]
  		FIG. 5.
Dose- and time-dependent effect of efavirenz on SREBP-1c, PPAR{gamma}, C/EBP{alpha}, and C/EBP{beta} mRNA levels and G3PDH activity in differentiating 3T3-F442A cells. Left panels, from confluence (day 0), 3T3-F442A cells were cultured until day 7 in the absence or in the presence of various concentrations of efavirenz. Right panels, from confluence, 3T3-F442A cells were maintained in the absence or in the presence of 40 µM efavirenz for the indicated intervals. For these two kinds of experimental conditions, total RNA was prepared, and SREBP-1c, PPAR{gamma}, and C/EBP{alpha} and -{beta} mRNA levels were determined by real time RT-PCR analysis. G3PDH activity was measured on cell supernatants. Control G3PDH activity were 27.6 ± 4.5, 254.1 ± 39.0, and 484.8 ± 31.8 nmol/min/mg in day 2, day 4, and day 7 postconfluent cells, respectively. Results are expressed as the percentage of control mRNA levels or G3PDH activity and represent the mean + S.E. of 4–10 separate experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001, efavirenz-treated versus control cells.

 
We also examined the time dependence of the down-regulation of these mRNA species. 3T3-F442A cells were cultured from confluence for 2, 4, or 7 days in the absence or in the presence of 40 µM efavirenz. Fig. 5 (right panels) indicates that as soon as a 2-day exposure to the NNRTI, we observed a dramatic decrease in SREBP-1c mRNA levels, which persisted below 10% of the control levels throughout the culture. Interestingly, following a 2- or 4-day treatment with efavirenz, we observed a decrease in the abundance of PPAR{gamma} and C/EBP{alpha} transcripts. However, after a 7-day exposure to the drug, there was a spontaneous recovery in PPAR{gamma} and C/EBP{alpha} gene expression. The time-dependent pattern of G3PDH activity is close to those of PPAR{gamma} and C/EBP{alpha} mRNAs. Finally, C/EBP{beta} mRNA levels were not influenced by efavirenz treatment during the course of the culture. Thus, whereas efavirenz induced a very potent and persistent down-regulation in SREBP-1c mRNA levels, it only provoked a transient decrease in PPAR{gamma} and C/EBP{alpha} gene expression, which only occurred at high NNRTI concentrations. Taken together, these observations support the view that efavirenz exerted a privileged and sustained inhibitory effect on the lipogenic pathway, whereas the limiting effect of the NNRTI on adipocyte differentiation was only observed at high concentrations.

To ensure that the variations in gene expression detected in real-time RT-PCR analysis were followed by parallel changes in the levels of the related proteins, Western blot analysis of SREBP-1c, PPAR{gamma}, and C/EBP{alpha} was performed on nuclear extracts of 3T3-F442A cells exposed to various efavirenz concentrations for 7 days (Fig. 6). In agreement with gene expression analysis, the mature nuclear form of SREBP-1c was sharply reduced by efavirenz, with a maximal decrease of 97% at a concentration of 50 µM. A marked down-regulation of C/EBP{alpha} was only clearly detectable at the two highest concentrations of the antiretroviral compound, reaching 18 and 3% of control levels at 40 and 50 µM efavirenz, respectively. Likewise, PPAR{gamma} expression was affected only at high efavirenz concentrations but with a maximal 50% decrease at 50 µM efavirenz.



View larger version (34K):
[in this window]
[in a new window]
  		FIG. 6.
Dose-dependent effect of efavirenz on SREBP-1c, PPAR{gamma}, and C/EBP{alpha} protein expression. From confluence (day 0), 3T3-F442A cells were cultured until day 7 in the absence or in the presence of various concentrations of efavirenz. Nuclear extracts were prepared as mentioned under "Experimental Procedures," and SREBP-1c, PPAR{gamma}, and C/EBP{alpha} protein expression was tested by Western blot analysis, using specific antisera available commercially. Each membrane was stained with Ponceau S to assess transfer efficiency and to estimate equal protein loading. A representative blot for each protein is shown. Three independent experiments were performed with similar results.

 
To investigate the functional consequences of SREBP-1c down-regulation by efavirenz, we examined the effects of the NNRTI on the expression of typical SREBP-1c target genes, such as those coding for fatty acid synthase (FAS) (22–24) and stearoyl-CoA desaturase-1 (SCD-1) (67). As controls, we also measured lipoprotein lipase (LPL) and adipocyte lipid-binding protein (aP2) mRNA levels, whose genes are targets for PPAR{gamma} and C/EBP{alpha} but not for SREBP-1c. As shown in Fig. 7, we observed a dramatic dose-dependent decrease in mRNA levels of FAS and SCD-1. This down-regulation was detectable as early as 5 µM and reached a plateau at 50 µM, where FAS and SCD-1 mRNA levels represented 12 and 2% of the control values, respectively. Time dependence studies also showed the same potent and persistent down-regulation of these two mRNA species (Fig. 7). Thus, the effect of efavirenz on SREBP-1c target genes closely paralleled that of SREBP-1c mRNA, in terms of both dose and time dependence. The pattern of LPL and aP2 mRNA regulation was different and more closely matched that observed for PPAR{gamma} and C/EBP{alpha}. Dose-response curves indicated that at day 7 following confluence, LPL and aP2 mRNA levels were only moderately suppressed by efavirenz, with a maximal 40–50% inhibitory effect. Interestingly, time dependence experiments demonstrate that after a clear 50–60% efavirenz-induced decrease in LPL and aP2 mRNA levels at day 2 or day 4 following confluence, there was a spontaneous tendency for recovering the levels of these mRNA species after a 7-day exposure to the drug. Thus, efavirenz induced a potent dose- and time-dependent down-regulation in SREBP-1c target gene expression, whereas LPL or aP2 mRNA levels were much less affected.



View larger version (37K):
[in this window]
[in a new window]
  		FIG. 7.
Dose- and time-dependent effect of efavirenz on mRNA levels of SREBP-1c-target genes in differentiating 3T3-F442A cells. Left panels, from confluence (day 0), 3T3-F442A cells were cultured until day 7 in the absence or in the presence of various concentrations of efavirenz. Right panels, from confluence (day 0), 3T3-F442A were maintained in the absence or in the presence of 40 µM efavirenz for the indicated intervals. For these two kinds of experimental conditions, total RNA was prepared, and FAS, SCD-1, LPL, and aP2 mRNA levels were determined by real time RT-PCR analysis. Results are expressed as the percentage of control mRNA levels and represent the mean ± S.E. of four or five separate experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001; n.s., nonsignificant, efavirenz-treated versus control cells.

 
This marked decrease in SREBP-1c and SREBP-1c targets was also found in the 3T3-L1 preadipose cell line and in primary culture of human preadipocytes. A chronic exposure of 3T3-L1 cells to various efavirenz concentrations for 7 days led to a dramatic decrease in SREBP-1c, FAS, and SCD-1 mRNA levels (not shown). Likewise, efavirenz markedly reduced SREBP-1c gene expression in human differentiating preadipocytes. Following a 7-day treatment with 4 µM efavirenz, and as compared with control cells, we observed a 82 and 76% decrease in SREBP-1c and FAS mRNA levels, respectively, whereas PPAR{gamma} gene expression remained unchanged.

To verify whether SREBP-1c regulation also exists in mature fat cells, we also measured SREBP-1c, FAS, and SCD-1 mRNA levels in fully differentiated 3T3-F442A adipocytes exposed from day 8 post-confluence to 40 µM efavirenz for 4 or 8 days (days 12 and 16 following confluence, respectively). After a 4-day treatment with the NNRTI, SREBP-1c, FAS, and SCD-1 mRNA levels were decreased by 32 ± 1, 60 ± 8, and 57 ± 5% in comparison with control levels, respectively. Following a 8-day exposure to efavirenz, the respective corresponding reductions were 97 ± 1, 97 ± 1, and 96 ± 3%. This effect was independent of a general dedifferentiating effect, as evaluated by measurement of G3PDH activity (not shown). Thus, in mature adipocytes, efavirenz induced a dramatic but delayed down-regulation in SREBP-1c, FAS, and SCD-1 gene expression.

Finally, in an attempt to demonstrate that the efavirenz-induced decrease in SREBP-1c expression was responsible for the major phenotypic changes, we examined whether an adenovirus-driven expression of SREBP-1c in NNRTI-treated cells could restore the cellular levels of triglycerides and mRNAs for SREBP-1c target genes. 3T3-F442A cells were cultured from confluence with or without 40 µM efavirenz. At day 4 following confluence, efavirenz-treated cells were infected either with Ad.null or with Ad.SREBP-1c DP, under conditions that allowed an optimal expression of SREBP-1c in 3T3 adipocytes (62). Thereafter, efavirenz was pursued for 48 h before determination of mRNA levels or for 96 h for triglyceride measurement. Control dishes were infected in parallel with the Ad-null vector. As shown in Fig. 8, infection with Ad.SREBP-1c DP almost completely reversed the inhibitory effect of efavirenz on cell triglyceride content. FAS and SCD-1 mRNA levels were decreased by 10- and 12-fold by efavirenz exposure, respectively. Infection of 3T3-F442A cells with Ad.SREBP-1c DP was able to restore normal FAS mRNA levels (12.5-fold induction as compared with efavirenz-treated cells infected with Ad.null vector) and induced an 8-fold increase in SCD-1 mRNA abundance. Thus, the expression of a dominant positive form of SREBP-1c restored the adipocyte triglyceride stores of efavirenz-treated cells, probably through an induction of the lipogenic pathway.



View larger version (32K):
[in this window]
[in a new window]
  		FIG. 8.
SREBP-1c transgene expression reverses efavirenz effect on triacylglycerol accumulation and gene expression. 3T3-F442A cells were cultured from confluence in the absence or in the presence of efavirenz (40 µM). At day 4 following confluence, efavirenz-treated cells were infected either with Ad.null or with Ad.SREBP-1c DP, and efavirenz was pursued. Control cells were infected with Ad.null. Since cells were cultured in the presence of insulin and because SREBP-1c expression is directly stimulated by insulin at the transcriptional level (76), the effect of SREBP-1c DP on cells untreated by efavirenz could not be assessed in this experiment. However, the positive effect of SREBP-1c DP on FAS or SCD-1 gene expression has been shown previously in 3T3 insulin-deprived adipocytes (62). After 48 h (day 6 after confluence), total RNA was prepared to evaluate FAS and SCD-1 mRNA levels by real time RT-PCR analysis. After 96 h (day 8 after confluence), cell homogenates were obtained to determine triglyceride content. Results are expressed as the percentage of control values and represent the mean ± S.E. of two independent experiments performed in duplicate. *, p < 0.05; **, p < 0.01, efavirenz-treated versus control cells. #, p < 0.05; ##, p < 0.001, efavirenz-treated cells infected with Ad.null versus efavirenz-treated cells infected with Ad.SREBP-1c DP.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
HAART has dramatically improved the prognosis of HIV-infected patients but has been involved in the emergence or aggravation of a metabolic syndrome with potentially severe consequences (9). The cellular and molecular mechanisms underlying these adverse effects remain poorly understood, but many studies converge to suggest that altered adipose tissue metabolism may have a key role in the development of this syndrome. It has been proposed that the widespread use of PIs may be an important determinant of HAART-induced lipodystrophy. However, the onset of the metabolic syndrome in therapy naive HIV-infected patients (13) or in HAARTs that exclude PIs (14–16) has underlined that other components of the antiretroviral regimen probably contribute to these severe metabolic complications. For instance, NRTIs, through their mitochondrial toxicity, may also be associated with hepatic steatosis and lactic acidemia (68). The increased risk of coronary heart disease, which appears particularly associated with PI-containing regimens (69), highlights the concept that other antiretroviral compounds with fewer side effects have a major interest in the treatment of HIV-infected patients. In this context, NNRTIs represent a promising approach to combine antiviral efficiency and limited adverse effects (70). So far, to our knowledge, no interference of NNRTIs on adipose tissue development or metabolism has been reported. In this work, we demonstrate that, during adipose conversion of 3T3 or human preadipocytes, the NNRTI efavirenz, used within the range of therapeutic plasma concentrations, prevents lipid storage and limits the extent of cell differentiation. These two effects display distinct sensitivities to efavirenz, with an inhibition of triglyceride accumulation occurring at lower concentrations of the drug than those required to detect an effect on adipogenesis. The NNRTI also depletes the lipid stores in mature adipocytes. This phenomenon is probably related to a strong reduction in the expression of the lipogenic transcription factor SREBP-1c. These results raise the possibility that this NNRTI may be involved in adipose tissue atrophy.

Efavirenz, when incubated with preadipocytes during the differentiation process, clearly prevents the cells from accumulating lipids. This effect is already detectable at the lowest efavirenz concentrations. We examined the cellular and molecular mechanisms by which the NNRTI provokes a dramatic decrease in cytoplasmic triacylglycerols. First, we excluded several mechanisms that could account, at least in part, for the efavirenz-induced reduction in cell lipid stores. Especially, neither basal nor isoproterenol- or forskolin-stimulated lipolysis are increased by efavirenz exposure, ruling out the possibility that the NNRTI depletes triglyceride stores through an activation of lipolysis. An alteration in cell viability seems also unlikely, since lactate dehydrogenase activity is not modified in the culture medium of efavirenz-treated cells and in regard to the rapid reversibility of the NNRTI effect after drug withdrawal. Otherwise, we excluded the possibility that efavirenz could reduce basal or insulin-stimulated glucose transport, resulting in a decreased substrate availability for de novo fatty acid biosynthesis.

By contrast, many experimental data converge to demonstrate that efavirenz exerts antilipogenic properties, which are mediated by a dramatic down-regulation in SREBP-1c expression. Efavirenz concentrations that reduce cell triglyceride content are lower than those required to alter adipocyte differentiation. This concentration gap between these two distinct effects, together with the exclusion of other potential mechanisms mentioned above, suggest that efavirenz preferentially targets lipogenesis instead of a general dedifferentiating effect. In keeping with this observation, efavirenz potently decreases SREBP-1c mRNA levels and the expression of the related mature 68-kDa protein. Because the mature form of SREBP-1c is known to promote lipogenic gene expression (71), the large decrease in the levels of the 68-kDa SREBP-1c protein probably contributes to impaired lipogenesis in efavirenz-treated cells. Delineation of the molecular transcriptional or post-transcriptional mechanisms at the basis of the down-regulation of SREBP-1c mRNA levels represents another issue. In agreement with efavirenz-induced down-regulation of SREBP-1c, we observe a reduction in adipocyte lipogenic activity and a dramatic decrease in the expression in SREBP-1c target genes, such as a marked suppression of the transcript coding for FAS, an important enzyme of lipogenesis. Finally, two complementary approaches strongly support the view that efavirenz-induced SREBP-1c suppression is a major mechanism to reduce cell triglyceride accumulation. First, efavirenz effect on lipid stores is completely prevented when the lipogenic pathway is bypassed by directly providing fatty acids to the cells. Second, an adenovirus-driven SREBP-1c overexpression restores the lipid stores and the expression of SREBP-1c target genes involved in lipogenesis. Thus, SREBP-1c down-regulation is very likely a central mechanism by which efavirenz reduces triglyceride content of fat cells.

At the highest concentrations (40–50 µM), efavirenz also alters the magnitude of adipocyte differentiation. This result can be brought together with the observation that C/EBP{alpha} and PPAR{gamma} gene and protein expression are decreased at this high dose of the NNRTI. Since C/EBP{alpha} and PPAR{gamma} are generally considered as major adipogenic transcription factors (21), efavirenz-induced impairment in adipose conversion could be related to this decrease in C/EBP{alpha} and PPAR{gamma} expression. Interestingly, because efavirenz effect on triglyceride accumulation is not reversed or prevented by the PPAR{gamma} agonist troglitazone (not shown), it seems unlikely that an alteration in PPAR{gamma} expression and/or function could represent a key mechanism for the NNRTI action. Otherwise, C/EBP{beta} mRNA levels are not influenced by efavirenz exposure, suggesting that molecular targets affected by the antiadipogenic properties of the antiretroviral drug are probably located downstream from this adipogenic transcription factor. Noticeably, the slightly delayed adipose conversion observed at high efavirenz concentrations is a transient phenomenon that tends to blur with progression of adipocyte differentiation. After an initial stronger suppression at day 2 or day 4 following confluence, PPAR{gamma} and C/EBP{alpha} mRNA levels increased at day 7 postconfluence. In keeping with this observation, the pattern of aP2 mRNA expression, which corresponds to a PPAR{gamma} and C/EBP{alpha} (21) target gene but not to a SREBP-1c target gene, is quite similar to that of PPAR{gamma} and C/EBP{alpha} transcripts. Thus, it is conceivable that along the course of the adipocyte differentiation process, a high concentration of efavirenz may only act during a limited window to delay adipose conversion.

The fact that mature adipocytes are less sensitive to efavirenz lipid-depleting effects than differentiating preadipocytes (a long term treatment with high doses of the NNRTI is required to observe a clear decrease in cell triglyceride content) deserves explanation. In the view that the SREBP-1c-controlled lipogenic pathway is preferentially targeted by efavirenz, one possibility could be that the contribution of de novo lipogenesis to triglyceride deposition might be different between lipid-accumulating preadipocytes and mature lipid-engorged fat cells. In keeping with this, the reesterification of preexisting fatty acids occurs at high rates in mature adipocytes, thus limiting the consequences of a blockade of lipogenesis. Alternatively, the functional features of the differentiated phenotype could enable the cells to circumvent the efavirenz-induced blockade of the lipogenic pathway. For instance, mature fat cells possess membrane and cytosolic transporters for fatty acids, which are not fully expressed in differentiating cells (72). Thus, triglyceride synthesis is probably more dependent on the lipogenic pathway in a differentiating preadipocyte than in a mature fat cell. Finally, the apparent lower efficiency of efavirenz in differentiated adipocytes could be related to differentiation-linked differences in drug inactivaction and/or to efavirenz intracellular distribution that might vary in a preadipocyte with very little triglyceride stores and in a lipid-laden adipocyte. Efavirenz is metabolized to some degree by members of the cytochrome P450 family (73). Whether changes in expression and/or function of this system of enzymes during adipose conversion could account for the differences in preadipocyte or adipocyte sensitivity to efavirenz remains an open question.

Efavirenz exerts its antilipogenic effect through a strong down-regulation of SREBP-1c expression. Interestingly, in preadipocytes and adipocytes, the same transcription factor SREBP-1c also represents a privileged target for several PIs. Nguyen et al. (74) have shown that during the differentiation of the 3T3-L1 cell line, ritonavir augments the accumulation of triglycerides by increasing the expression of the 68-kDa mature form of SREBP-1c. In vivo, ritonavir induces the accumulation of activated SREBP-1c in the nucleus of rat liver and adipose tissue (36). However, studies have reported an alteration in SREBP-1c expression or function in response to other PIs. Dowell et al. (31) have shown that nelfinavir inhibits accumulation of mature 68-kDa SREBP-1c protein in 3T3-L1 cells, whereas indinavir induces an abnormal sequestration of SREBP-1c at the nuclear membrane (32, 34) and inhibits the expression of SREBP-1c target genes (35). Finally, HIV-infected patients treated with a combination of NRTIs and PIs have a greatly reduced SREBP-1c expression in lipoatrophic superficial fat depots (37). Thus, SREBP-1c seems to be a major target in the setting of the metabolic syndrome and could play a critical role in adipose tissue dysfunction observed during HAART. Although it is generally considered that PIs are probably responsible for most of the SREBP-1c-mediated adipocyte alterations, the present study demonstrates that the same pathway is targeted by other antiretroviral compounds, including the NNRTI efavirenz. Such a convergence in the effects of PIs and efavirenz on SREBP-1c, revealed by this and other studies on adipocytes, raises the intriguing question of the existence of a potential link between the antiretroviral activity of these molecules and the SREBP-1c pathway.

The concentrations of efavirenz required to elicit its effects on lipogenesis are within the range of those observed in plasma from patients receiving therapeutic doses of this antiretroviral agent (63, 64). Thus, it is possible that the effects of efavirenz on the 3T3-F442A and 3T3-L1 cell lines and on human preadipocytes observed in vitro may also occur in vivo. Interestingly, a recent work has reported that in HIV-infected patients receiving an antiretroviral treatment, efavirenz can accumulate in fat tissue (52). This accumulation of the drug in adipose tissue may facilitate the onset of its adverse effects on preadipocyte and adipocyte development and metabolism. However, we demonstrate in this work that efavirenz primarily alters the lipogenic pathway in differentiating or mature fat cells. It is generally recognized that whereas the lipogenic activity has a central role in energy storage in cultured preadipose cell lines and in adipose tissue from rodent species, this pathway has been reported to exert an accessory function in human adipose tissue (75). In humans, the liver is the central organ for de novo lipogenesis. As suggested by our experimental results, the antilipogenic properties of efavirenz in adipocyte could be counteracted by sufficient availability of exogenous free fatty acids, which are probably present in vivo. However, the accumulation of efavirenz in adipose tissue (52) may favor an antiadipogenic effect in addition to its antilipogenic action. Thus, despite the sharp efavirenz-induced depletion in lipid stores detected on several in vitro models of preadipocyte and adipocyte, further experimental and clinical investigations will be helpful to ascertain the medical relevance of our observations. Otherwise, whether efavirenz also alters lipogenesis in hepatocytes in vitro or in vivo represents a major issue.


   FOOTNOTES
 
* This work was supported by grants from the Agence Nationale de Recherche sur le SIDA. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

§ These two authors contributed equally to this work. Back

** To whom correspondence should be addressed. Tel.: 33-1-42-34-68-81; Fax: 33-1-46-34-59-73; E-mail: feve{at}bhdc.jussieu.fr.

1 The abbreviations used are: HAART, highly active antiretroviral therapy; Ad.null, adenovirus containing no exogenous gene; Ad. SREBP-1c DP, adenovirus containing a dominant positive form of SREBP-1c; aP2, adipocyte lipid-binding protein; BSA, bovine serum albumin; C/EBP, CCAAT/enhancer-binding protein; DMEM, Dulbecco's modified Eagle's medium; [3H]DOG, [1,2-3H]deoxyglucose; FAS, fatty acid synthase; G3PDH, glycerol-3-phosphate dehydrogenase; HIV, human immunodeficiency virus; KRH, Krebs Ringer Hepes; LPL, lipoprotein lipase; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PBS, phosphate-buffered saline; PI, protease inhibitor; PPAR{gamma}, peroxisome proliferator-activated receptor-{gamma}; RT, reverse transcriptase; SREBP-1c, sterol regulatory element-binding protein-1c; SCD-1, stearoyl-CoA desaturase-1; ADD1, adipocyte determination and differentiation factor-1. Back


   ACKNOWLEDGMENTS
 
We thank M. C. Leneveu for expert technical assistance and Prof. M. Raymondjean for a critical review of the manuscript. Efavirenz was a generous gift of Bristol-Myers Squibb Laboratories.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Jr., Feinberg, J. E., Balfour, H. H., Jr., Deyton, L. R., Chodakewitz, J. A., and Fischl, M. A. (1997) N. Engl. J. Med. 337, 725-733[Abstract/Free Full Text]
  2. Palella, F. J., Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., and Holmberg, S. D. (1998) N. Engl. J. Med. 338, 853-860[Abstract/Free Full Text]
  3. Finzi, D., Blankson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., Quinn, T. C., Chaisson, R. E., Rosenberg, E., Walker, B., Gange, S., Gallant, J., and Siliciano, R. F. (1999) Nat. Med. 5, 512-517[CrossRef][Medline] [Order article via Infotrieve]
  4. Flexner, C. (1998) N. Engl. J. Med. 338, 1281-1292[Free Full Text]
  5. Beach, J. W. (1998) Clin. Ther. 20, 2-25[CrossRef][Medline] [Order article via Infotrieve]
  6. Miller, K. D., Jones, E., Yanovski, J. A., Shankar, R., Feuerstein, I., and Falloon, J. (1998) Lancet 351, 871-875[CrossRef][Medline] [Order article via Infotrieve]
  7. Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., and Cooper, D. A. (1998) AIDS 12, F51-58[CrossRef][Medline] [Order article via Infotrieve]
  8. Stocker, D. N., Meier, P. J., Stoller, R., and Fattinger, K. E. (1998) Lancet 352, 320-321[Medline] [Order article via Infotrieve]
  9. Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G. R., Chisholm, D. J., and Cooper, D. A. (1999) Lancet 353, 2093-2099[CrossRef][Medline] [Order article via Infotrieve]
  10. Walli, R., Herfort, O., Michl, G. M., Demant, T., Jager, H., Dieterle, C., Bogner, J. R., Landgraf, R., and Goebel, F. D. (1998) AIDS 12, F167-F173[CrossRef][Medline] [Order article via Infotrieve]
  11. Vigouroux, C., Gharakhanian, S., Salhi, Y., Nguyen, T. H., Chevenne, D., Capeau, J., and Rozenbaum, W. (1999) Diabetes Metab. 25, 225-232[Medline] [Order article via Infotrieve]
  12. Holmberg, S. D., Moorman, A. C., Williamson, J. M., Tong, T. C., Ward, D. J., Wood, K. C., Greenberg, A. E., and Janssen, R. S. (2002) Lancet 360, 1747-1748[CrossRef][Medline] [Order article via Infotrieve]
  13. Kotler, D. P., Rosenbaum, K., Wang, J., and Pierson, R. N. (1999) J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 20, 228-237[Medline] [Order article via Infotrieve]
  14. Lo, J. C., Mulligan, K., Tai, V. W., Algren, H., and Schambelan, M. (1998) Lancet 351, 867-870[CrossRef][Medline] [Order article via Infotrieve]
  15. Madge, S., Kinloch-de-Loes, S., Mercey, D., Johnson, M. A., and Weller, I. V. (1999) AIDS 13, 735-737[CrossRef][Medline] [Order article via Infotrieve]
  16. Saint-Marc, T., Partisani, M., Poizot-Martin, I., Bruno, F., Rouviere, O., Lang, J. M., Gastaut, J. A., and Touraine, J. L. (1999) AIDS 13, 1659-1667[CrossRef][Medline] [Order article via Infotrieve]
  17. Garg, A. (2000) Am. J. Med. 108, 143-152[CrossRef][Medline] [Order article via Infotrieve]
  18. Moitra, J., Mason, M. M., Olive, M., Krylov, D., Gavrilova, O., Marcus-Samuels, B., Feigenbaum, L., Lee, E., Aoyama, T., Eckhaus, M., Reitman, M. L., and Vinson, C. (1998) Genes Dev. 12, 3168-3181[Abstract/Free Full Text]
  19. Shimomura, I., Hammer, R. E., Richardson, J. A., Ikemoto, S., Bashmakov, Y., Goldstein, J. L., and Brown, M. S. (1998) Genes Dev. 12, 3182-3194[Abstract/Free Full Text]
  20. Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., Ezaki, O., Akanuma, Y., Gavrilova, O., Vinson, C., Reitman, M. L., Kagechika, H., Shudo, K., Yoda, M., Nakano, Y., Tobe, K., Nagai, R., Kimura, S., Tomita, M., Froguel, P., and Kadowaki, T. (2001) Nat. Med. 7, 941-946[CrossRef][Medline] [Order article via Infotrieve]
  21. Rosen, E. D., Walkey, C. J., Puigserver, P., and Spiegelman, B. M. (2000) Genes Dev. 14, 1293-1307[Free Full Text]
  22. Kim, J. B., and Spiegelman, B. M. (1996) Genes Dev. 10, 1096-1107[Abstract/Free Full Text]
  23. Bennett, M. K., Lopez, J. M., Sanchez, H. B., and Osborne, T. F. (1995) J. Biol. Chem. 270, 25578-25583[Abstract/Free Full Text]
  24. Boizard, M., Le Liepvre, X., Lemarchand, P., Foufelle, F., Ferre, P., and Dugail, I. (1998) J. Biol. Chem. 273, 29164-29171[Abstract/Free Full Text]
  25. Fajas, L., Schoonjans, K., Gelman, L., Kim, J. B., Najib, J., Martin, G., Fruchart, J. C., Briggs, M., Spiegelman, B. M., and Auwerx, J. (1999) Mol. Cell. Biol. 19, 5495-5503[Abstract/Free Full Text]
  26. Kim, J. B., Wright, H. M., Wright, M., and Spiegelman, B. M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 4333-4337[Abstract/Free Full Text]
  27. Gagnon, A., Angel, J. B., and Sorisky, A. (1998) Lancet 352, 1032[CrossRef][Medline] [Order article via Infotrieve]
  28. Zhang, B., MacNaul, K., Szalkowski, D., Li, Z., Berger, J., and Moller, D. E. (1999) J. Clin. Endocrinol. Metab. 84, 4274-4277[Abstract/Free Full Text]
  29. Wentworth, J. M., Burris, T. P., and Chatterjee, V. K. (2000) J. Endocrinol. 164, R7-R10[Abstract]
  30. Lenhard, J. M., Furfine, E. S., Jain, R. G., Ittoop, O., Orband-Miller, L. A., Blanchard, S. G., Paulik, M. A., and Weiel, J. E. (2000) Antiviral Res. 47, 121-129[CrossRef][Medline] [Order article via Infotrieve]
  31. Dowell, P., Flexner, C., Kwiterovich, P. O., and Lane, M. D. (2000) J. Biol. Chem. 275, 41325-41332[Abstract/Free Full Text]
  32. Caron, M., Auclair, M., Vigouroux, C., Glorian, M., Forest, C., and Capeau, J. (2001) Diabetes 50, 1378-1388[Abstract/Free Full Text]
  33. Vernochet, C., Azoulay, S., Duval, D., Guedj, R., Ailhaud, G., and Dani, C. (2003) AIDS 17, 2177-2180[CrossRef][Medline] [Order article via Infotrieve]
  34. Caron, M., Auclair, M., Sterlingot, H., Kornprobst, M., and Capeau, J. (2003) AIDS 17, 2437-2444[CrossRef][Medline] [Order article via Infotrieve]
  35. Miserez, A. R., Muller, P. Y., and Spaniol, V. (2002) AIDS 16, 1587-1594[CrossRef][Medline] [Order article via Infotrieve]
  36. Riddle, T. M., Kuhel, D. G., Woollett, L. A., Fichtenbaum, C. J., and Hui, D. Y. (2001) J. Biol. Chem. 276, 37514-37519[Abstract/Free Full Text]
  37. Bastard, J. P., Caron, M., Vidal, H., Jan, V., Auclair, M., Vigouroux, C., Luboinski, J., Laville, M., Maachi, M., Girard, P. M., Rozenbaum, W., Levan, P., and Capeau, J. (2002) Lancet 359, 1026-1031[CrossRef][Medline] [Order article via Infotrieve]
  38. Nerurkar, P. V., Shikuma, C. M., and Nerurkar, V. R. (2001) Clin. Biochem. 34, 519-529[CrossRef][Medline] [Order article via Infotrieve]
  39. Murata, H., Hruz, P. W., and Mueckler, M. (2000) J. Biol. Chem. 275, 20251-20254[Abstract/Free Full Text]
  40. Rudich, A., Vanounou, S., Riesenberg, K., Porat, M., Tirosh, A., Harman-Boehm, I., Greenberg, A. S., Schlaeffer, F., and Bashan, N. (2001) Diabetes 50, 1425-1431[Abstract/Free Full Text]
  41. Domingo, P., Matias-Guiu, X., Pujol, R. M., Francia, E., Lagarda, E., Sambeat, M. A., and Vazquez, G. (1999) AIDS 13, 2261-2267[CrossRef][Medline] [Order article via Infotrieve]
  42. Clumeck, N., Goebel, F., Rozenbaum, W., Gerstoft, J., Staszewski, S., Montaner, J., Johnson, M., Gazzard, B., Stone, C., Athisegaran, R., and Moore, S. (2001) AIDS 15, 1517-1526[CrossRef][Medline] [Order article via Infotrieve]
  43. Martinez, E., Arnaiz, J. A., Podzamczer, D., Dalmau, D., Ribera, E., Domingo, P., Knobel, H., Riera, M., Pedrol, E., Force, L., Llibre, J. M., Segura, F., Richart, C., Cortes, C., Javaloyas, M., Aranda, M., Cruceta, A., de Lazzari, E., and Gatell, J. M. (2003) N. Engl. J. Med. 349, 1036-1046[Abstract/Free Full Text]
  44. Martinez, E., Conget, I., Lozano, L., Casamitjana, R., and Gatell, J. M. (1999) AIDS 13, 805-810[CrossRef][Medline] [Order article via Infotrieve]
  45. Dieleman, J. P., Gyssens, I. C., Sturkenboom, M. J., Niesters, H. G., and van der Ende, M. E. (1999) AIDS 13, 1423-1424[Medline] [Order article via Infotrieve]
  46. Barreiro, P., Soriano, V., Blanco, F., Casimiro, C., de la Cruz, J. J., and Gonzalez-Lahoz, J. (2000) AIDS 14, 807-812[CrossRef][Medline] [Order article via Infotrieve]
  47. Rey, D., Schmitt, M. P., Partisani, M., Hess-Kempf, G., Krantz, V., de Mautort, E., Bernard-Henry, C., Priester, M., Cheneau, C., and Lang, J. M. (2001) J. Acquired Immune Defic. Syndr. 27, 459-462
  48. Hirschel, B., Flepp, M., Bucher, H. C., Zellweger, C., Telenti, A., Wagels, T., Bernasconi, E., and Ledergerber, B. (2002) AIDS 16, 381-385[CrossRef][Medline] [Order article via Infotrieve]
  49. Hsieh, S. M., Hung, C. C., Lu, P. L., Chen, M. Y., and Chang, S. C. (2000) J. Acquired Immune Defic. Syndr. 24, 287-288
  50. Doser, N., Sudre, P., Telenti, A., Wietlisbach, V., Nicod, P., Darioli, R., and Mooser, V. (2001) J. Acquired Immune Defic. Syndr. 26, 389-390
  51. Bonnet, F., Bonarek, M., De Witte, S., Beylot, J., and Morlat, P. (2002) Clin. Infect. Dis. 35, 776-777[Medline] [Order article via Infotrieve]
  52. Dupin, N., Buffet, M., Marcelin, A. G., Lamotte, C., Gorin, I., Ait-Arkoub, Z., Treluyer, J. M., Bui, P., Calvez, V., and Peytavin, G. (2002) AIDS 16, 2419-2424[CrossRef][Medline] [Order article via Infotrieve]
  53. Dieudonne, M. N., Pecquery, R., Boumediene, A., Leneveu, M. C., and Giudicelli, Y. (1998) Am. J. Physiol. 274, C1645-C1652
  54. Lowry, O., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275[Free Full Text]
  55. Kozak, L. P., and Jensen, J. T. (1974) J. Biol. Chem. 249, 7775-7781[Abstract/Free Full Text]
  56. Green, A., Dobias, S. B., Walters, D. J., and Brasier, A. R. (1994) Endocrinology 134, 2581-2588[Abstract/Free Full Text]
  57. Folch, J., Lees, M., and Sloane Stanley, G. H. (1957) J. Biol. Chem. 226, 497-509[Free Full Text]
  58. Cathala, G., Savouret, J. F., Mendez, B., West, B. L., Karin, M., Martial, J. A., and Baxter, J. D. (1983) DNA 2, 329-335[Medline] [Order article via Infotrieve]
  59. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159[Medline] [Order article via Infotrieve]
  60. Rolland, V., Dugail, I., Le Liepvre, X., and Lavau, M. (1995) J. Biol. Chem. 270, 1102-1106[Abstract/Free Full Text]
  61. Foretz, M., Guichard, C., Ferre, P., and Foufelle, F. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 12737-12742[Abstract/Free Full Text]
  62. Le Lay, S., Lefrere, I., Trautwein, C., Dugail, I., and Krief, S. (2002) J. Biol. Chem. 277, 35625-35634[Abstract/Free Full Text]
  63. Tashima, K. T., Caliendo, A. M., Ahmad, M., Gormley, J. M., Fiske, W. D., Brennan, J. M., and Flanigan, T. P. (1999) J. Infect. Dis. 180, 862-864[CrossRef][Medline] [Order article via Infotrieve]
  64. Langmann, P., Weissbrich, B., Desch, S., Vath, T., Schirmer, D., Zilly, M., and Klinker, H. (2002) Eur. J. Med. Res. 7, 309-314[Medline] [Order article via Infotrieve]
  65. Boffito, M., Back, D. J., Blaschke, T. F., Rowland, M., Bertz, R. J., Gerber, J. G., and Miller, V. (2003) AIDS Res. Hum. Retroviruses 19, 825-835[CrossRef][Medline] [Order article via Infotrieve]
  66. Pairault, J., and Green, H. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 5138-5142[Abstract/Free Full Text]
  67. Tabor, D. E., Kim, J. B., Spiegelman, B. M., and Edwards, P. A. (1998) J. Biol. Chem. 273, 22052-22058[Abstract/Free Full Text]
  68. Ogedegbe, A. E., Thomas, D. L., and Diehl, A. M. (2003) Lancet Infect. Dis. 3, 329-337[CrossRef][Medline] [Order article via Infotrieve]
  69. Grinspoon, S. (2001) Trends Endocrinol. Metab. 12, 413-419[Medline] [Order article via Infotrieve]
  70. van der Valk, M., and Reiss, P. (2003) Curr. Opin. Infect. Dis. 16, 19-23[Medline] [Order article via Infotrieve]
  71. Foufelle, F., and Ferre, P. (2002) Biochem. J. 366, 377-391[CrossRef][Medline] [Order article via Infotrieve]
  72. Gregoire, F. M., Smas, C. M., and Sul, H. S. (1998) Physiol. Rev. 78, 783-809[Abstract/Free Full Text]
  73. Smith, P. F., DiCenzo, R., and Morse, G. D. (2001) Clin. Pharmacokinet. 40, 893-905[CrossRef][Medline] [Order article via Infotrieve]
  74. Nguyen, A. T., Gagnon, A., Angel, J. B., and Sorisky, A. (2000) AIDS 14, 2467-2473[CrossRef][Medline] [Order article via Infotrieve]
  75. Diraison, F., Yankah, V., Letexier, D., Dusserre, E., Jones, P., and Beylot, M. (2003) J. Lipid Res. 44, 846-853[Abstract/Free Full Text]
  76. Kim, J. B., Sarraf, P., Wright, M., Yao, K. M., Mueller, E., Solanes, G., Lowell, B. B., and Spiegelman, B. M. (1998) J. Clin. Invest. 101, 1-9[Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J Int Assoc Physicians AIDS Care (Chic Ill)Home page
R. J. Bedimo
Body-Fat Abnormalities in Patients With HIV: Progress and Challenges
J Int Assoc Physicians AIDS Care (Chic Ill), December 1, 2008; 7(6): 292 - 305.
[Abstract] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. A. Perez-Molina, P. Domingo, E. Martinez, and S. Moreno
The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy
J. Antimicrob. Chemother., August 1, 2008; 62(2): 234 - 245.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. Roth, R. Looser, M. Kaufmann, S. M. Blattler, F. Rencurel, W. Huang, D. D. Moore, and U. A. Meyer
Regulatory Cross-Talk between Drug Metabolism and Lipid Homeostasis: Constitutive Androstane Receptor and Pregnane X Receptor Increase Insig-1 Expression
Mol. Pharmacol., April 1, 2008; 73(4): 1282 - 1289.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Vernochet, S. Azoulay, D. Duval, R. Guedj, F. Cottrez, H. Vidal, G. Ailhaud, and C. Dani
Human Immunodeficiency Virus Protease Inhibitors Accumulate into Cultured Human Adipocytes and Alter Expression of Adipocytokines
J. Biol. Chem., January 21, 2005; 280(3): 2238 - 2243.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/15/15130    most recent
M312875200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hadri, K. E.
Right arrow Articles by Fève, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hadri, K. E.
Right arrow Articles by Fève, B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement